



Drug Use Research & Management Program
 DHS - Health Systems Division
 500 Summer Street NE, E35, Salem, OR 97301-1079
 Phone 503-947-5220 | Fax 503-947-1119

College of Pharmacy

Pharmacy Utilization Summary Report: July 2024 - June 2025

Eligibility	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Avg Monthly
Total Members (FFS & Encounter)	1,226,816	1,235,264	1,241,007	1,247,678	1,254,503	1,257,986	1,241,274	1,243,854	1,234,473	1,242,572	1,246,331	1,249,863	1,243,468
FFS Members	98,771	97,509	96,865	99,056	99,856	98,868	99,039	93,047	91,577	91,602	90,100	89,262	95,463
OHP Basic with Medicare	8,606	8,437	8,250	8,222	7,915	7,437	7,659	7,451	7,022	6,746	6,382	6,097	7,519
OHP Basic without Medicare	9,308	9,241	9,221	9,278	9,034	8,899	8,472	8,170	8,072	8,028	8,016	7,876	8,635
ACA	80,857	79,831	79,394	81,556	82,907	82,532	82,908	77,426	76,483	76,828	75,702	75,289	79,309
Encounter Members	1,128,045	1,137,755	1,144,142	1,148,622	1,154,647	1,159,118	1,142,235	1,150,807	1,142,896	1,150,970	1,156,231	1,160,601	1,148,006
OHP Basic with Medicare	107,175	107,413	106,294	103,103	98,130	90,342	82,625	80,472	75,440	76,700	77,380	77,913	90,249
OHP Basic without Medicare	66,835	66,785	66,566	66,469	66,271	65,605	64,002	63,793	62,866	62,847	62,790	62,724	64,796
ACA	954,035	963,557	971,282	979,050	990,246	1,003,171	995,608	1,006,542	1,004,590	1,011,423	1,016,061	1,019,964	992,961

Gross Cost Figures for Drugs	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	YTD Sum
Total Amount Paid (FFS & Encounter)	\$132,160,636	\$130,407,285	\$128,296,462	\$141,572,425	\$126,844,169	\$139,444,267	\$145,920,046	\$132,492,369	\$148,003,833	\$150,392,854	\$146,777,578	\$147,211,663	\$1,669,523,586
Mental Health Carve-Out Drugs	\$12,108,246	\$11,876,191	\$11,493,038	\$13,459,508	\$11,704,615	\$14,415,165	\$14,620,898	\$13,505,172	\$14,851,170	\$15,614,328	\$15,274,033	\$15,635,947	\$164,558,312
OHP Basic with Medicare	\$3,424	\$76	\$6,734	\$10,098	\$9,432	\$1,264	\$6,525	\$5,748	\$2,268	\$5,567	\$8,358	\$10,675	\$70,169
OHP Basic without Medicare	\$4,268,712	\$4,211,876	\$4,019,845	\$4,500,610	\$3,944,225	\$4,744,989	\$4,547,643	\$4,597,080	\$5,044,491	\$4,923,201	\$4,721,568	\$4,596,029	\$54,120,271
ACA	\$6,799,278	\$6,621,741	\$6,575,688	\$7,603,453	\$6,779,982	\$8,386,186	\$8,532,090	\$7,517,012	\$8,474,840	\$9,005,276	\$8,724,906	\$8,758,876	\$93,779,329
FFS Physical Health Drugs	\$2,495,306	\$2,251,045	\$2,292,703	\$2,160,929	\$1,777,472	\$2,156,677	\$2,390,056	\$2,251,098	\$2,215,439	\$2,260,280	\$2,254,652	\$2,122,760	\$26,628,417
OHP Basic with Medicare	\$32,196	\$29,391	\$27,882	\$30,120	\$27,308	\$28,640	\$29,726	\$28,857	\$27,392	\$26,157	\$24,643	\$23,138	\$335,450
OHP Basic without Medicare	\$749,985	\$648,776	\$677,035	\$660,666	\$540,675	\$642,047	\$678,897	\$705,072	\$664,963	\$718,207	\$654,374	\$596,544	\$7,937,240
ACA	\$1,510,864	\$1,413,528	\$1,404,585	\$1,327,807	\$1,065,971	\$1,282,350	\$1,372,539	\$1,218,140	\$1,281,407	\$1,245,636	\$1,302,335	\$1,192,275	\$15,617,436
FFS Physician Administered Drugs	\$1,300,458	\$1,518,262	\$923,560	\$1,361,959	\$1,611,340	\$1,250,650	\$1,800,570	\$1,664,207	\$1,516,355	\$1,728,301	\$1,127,540	\$952,930	\$16,756,131
OHP Basic with Medicare	\$127,195	\$163,013	\$131,847	\$132,502	\$86,148	\$123,545	\$144,386	\$87,070	\$120,993	\$113,750	\$60,505	\$72,595	\$1,363,549
OHP Basic without Medicare	\$192,566	\$295,895	\$53,301	\$313,764	\$432,161	\$191,592	\$236,124	\$104,311	\$355,792	\$293,199	\$167,273	\$114,459	\$2,750,438
ACA	\$421,952	\$475,672	\$463,173	\$503,412	\$614,921	\$532,339	\$758,063	\$573,858	\$408,817	\$608,842	\$341,473	\$326,322	\$6,028,844
Encounter Physical Health Drugs	\$87,543,228	\$86,325,448	\$86,459,140	\$93,156,186	\$84,761,785	\$90,906,200	\$92,893,909	\$86,087,784	\$95,296,057	\$97,592,204	\$95,969,111	\$93,361,563	\$1,090,352,614
OHP Basic with Medicare	\$391,042	\$390,491	\$398,007	\$429,484	\$352,769	\$334,681	\$368,020	\$337,457	\$355,256	\$382,503	\$373,055	\$346,527	\$4,459,293
OHP Basic without Medicare	\$19,157,031	\$18,827,273	\$17,944,974	\$19,634,207	\$17,566,872	\$18,915,414	\$19,324,853	\$17,085,554	\$18,639,646	\$19,002,447	\$18,042,481	\$17,690,553	\$221,831,305
ACA	\$57,111,891	\$56,628,124	\$57,535,903	\$61,319,839	\$56,103,719	\$60,505,861	\$60,636,038	\$56,571,698	\$62,558,865	\$64,382,712	\$63,591,033	\$61,179,720	\$718,125,402
Encounter Physician Administered Drugs	\$28,713,397	\$28,436,340	\$27,128,021	\$31,433,843	\$26,988,957	\$30,715,576	\$34,214,613	\$28,984,108	\$34,124,811	\$33,197,741	\$32,152,242	\$35,138,463	\$371,228,112
OHP Basic with Medicare	\$1,091,319	\$1,008,440	\$971,586	\$1,129,581	\$801,494	\$801,219	\$1,157,258	\$804,840	\$758,640	\$824,445	\$724,763	\$713,309	\$10,786,896
OHP Basic without Medicare	\$6,253,229	\$6,151,513	\$5,444,588	\$6,360,472	\$5,343,141	\$5,793,715	\$5,662,636	\$5,910,499	\$9,415,729	\$6,043,170	\$5,912,843	\$5,874,448	\$74,165,984
ACA	\$18,035,790	\$17,819,546	\$17,008,139	\$19,895,387	\$17,633,831	\$19,777,242	\$22,911,282	\$17,485,364	\$18,988,410	\$20,561,312	\$19,768,241	\$22,930,857	\$232,815,399

OHP = Oregon Health Plan

ACA = Affordable Care Act expansion



Amount Paid on the Claim = 1) Ingredient Cost ((AAAC/NADAC/WAC) x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount

Last Updated: January 17, 2026



Pharmacy Utilization Summary Report: July 2024 - June 2025

YTD Percent Paid Amounts



OHP = Oregon Health Plan
ACA = Affordable Care Act expansion
PAD = Physician-administered drugs
Amount Paid on the Claim = 1) Ingredient Cost ([AAAC/NADAC/WAC] x Dispense Quantity) + Dispensing Fee.
If Billed Amount is lower, pay Billed Amount, 2) - TPL amount




Pharmacy Utilization Summary Report: July 2024 - June 2025

Quarterly Rebates Invoiced	2024-Q3	2024-Q4	2025-Q1	2025-Q2	YTD Sum
Total Rebate Invoiced (FFS & Encounter)	\$116,953,793	\$119,367,641	\$136,316,202	\$137,659,267	\$510,296,903
CMS MH Carve-out	\$12,780,546	\$13,564,774	\$15,447,598	\$15,406,762	\$57,199,680
SR MH Carve-out	\$2,915,315	\$3,354,368	\$3,055,632	\$3,579,531	\$12,904,846
CMS FFS Drug	\$4,185,987	\$3,278,456	\$4,222,441	\$3,778,521	\$15,465,405
SR FFS	\$508,647	\$481,787	\$651,850	\$736,281	\$2,378,565
CMS Encounter	\$93,564,912	\$95,614,931	\$111,307,781	\$112,306,159	\$412,793,783
SR Encounter	\$2,998,386	\$3,073,325	\$1,630,900	\$1,852,013	\$9,554,624

Quarterly Net Drug Costs	2024-Q3	2024-Q4	2025-Q1	2025-Q2	YTD Sum
Estimated Net Drug Costs (FFS & Encounter)	\$273,910,590	\$288,493,220	\$290,100,046	\$306,722,828	\$1,159,226,683
Mental Health Carve-Out Drugs	\$19,781,615	\$22,660,145	\$24,474,011	\$27,538,015	\$94,453,785
FFS Phys Health + PAD	\$6,086,700	\$6,558,783	\$6,963,433	\$5,931,662	\$25,540,578
Encounter Phys Health + PAD	\$248,042,276	\$259,274,291	\$258,662,602	\$273,253,151	\$1,039,232,320

YTD Percent Rebates Invoiced



SR = Supplemental Rebate
 CMS = Center for Medicaid Services
 PAD = Physician-administered drugs
 MH = Mental Health



Pharmacy Utilization Summary Report: July 2024 - June 2025

Gross PMPM Drug Costs (Rebates not Subtracted)	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Avg Monthly
PMPM Amount Paid (FFS & Encounter)	\$107.73	\$105.57	\$103.38	\$113.47	\$101.11	\$110.85	\$117.56	\$106.52	\$119.89	\$121.03	\$117.77	\$117.78	\$111.89
Mental Health Carve-Out Drugs	\$9.87	\$9.61	\$9.26	\$10.79	\$9.33	\$11.46	\$11.78	\$10.86	\$12.03	\$12.57	\$12.26	\$12.51	\$11.03
FFS Physical Health Drugs	\$25.26	\$23.09	\$23.67	\$21.82	\$17.80	\$21.81	\$24.13	\$24.19	\$24.19	\$24.68	\$25.02	\$23.78	\$23.29
FFS Physician Administered Drugs	\$13.17	\$15.57	\$9.53	\$13.75	\$16.14	\$12.65	\$18.18	\$17.89	\$16.56	\$18.87	\$12.51	\$10.68	\$14.62
Encounter Physical Health Drugs	\$77.61	\$75.87	\$75.57	\$81.10	\$73.41	\$78.43	\$81.33	\$74.81	\$83.38	\$84.79	\$83.00	\$80.44	\$79.14
Encounter Physician Administered Drugs	\$25.45	\$24.99	\$23.71	\$27.37	\$23.37	\$26.50	\$29.95	\$25.19	\$29.86	\$28.84	\$27.81	\$30.28	\$26.94

Claim Counts	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Avg Monthly
Total Claim Count (FFS & Encounter)	1,280,032	1,251,239	1,238,639	1,339,861	1,233,811	1,319,063	1,369,962	1,242,925	1,354,754	1,379,301	1,364,510	1,319,182	1,307,773
Mental Health Carve-Out Drugs	213,698	208,391	205,171	222,216	204,497	221,231	229,272	209,597	228,441	230,329	227,780	224,414	218,753
FFS Physical Health Drugs	28,226	25,562	25,271	26,880	24,305	26,412	29,491	26,292	27,642	27,281	25,851	24,582	26,483
FFS Physician Administered Drugs	8,712	8,212	8,012	8,381	7,282	7,819	9,983	8,789	8,886	8,872	8,591	8,152	8,474
Encounter Physical Health Drugs	895,799	876,837	872,536	941,603	866,204	926,625	955,293	863,283	946,936	962,790	950,540	915,665	914,509
Encounter Physician Administered Drugs	133,597	132,237	127,649	140,781	131,523	136,976	145,923	134,964	142,849	150,029	151,748	146,369	139,554

Gross Amount Paid per Claim (Rebates not Subtracted)	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Avg Monthly
Average Paid / Claim (FFS & Encounter)	\$103.25	\$104.22	\$103.58	\$105.66	\$102.81	\$105.71	\$106.51	\$106.60	\$109.25	\$109.04	\$107.57	\$111.59	\$106.32
Mental Health Carve-Out Drugs	\$56.66	\$56.99	\$56.02	\$60.57	\$57.24	\$65.16	\$63.77	\$64.43	\$65.01	\$67.79	\$67.06	\$69.67	\$62.53
FFS Physical Health Drugs	\$88.40	\$88.06	\$90.72	\$80.39	\$73.13	\$81.66	\$81.04	\$85.62	\$80.15	\$82.85	\$87.22	\$86.35	\$83.80
FFS Physician Administered Drugs	\$149.27	\$184.88	\$115.27	\$162.51	\$221.28	\$159.95	\$180.36	\$189.35	\$170.65	\$194.80	\$131.25	\$116.90	\$164.71
Encounter Physical Health Drugs	\$97.73	\$98.45	\$99.09	\$98.93	\$97.85	\$98.10	\$97.24	\$99.72	\$100.64	\$101.36	\$100.96	\$101.96	\$99.34
Encounter Physician Administered Drugs	\$214.93	\$215.04	\$212.52	\$223.28	\$205.20	\$224.24	\$234.47	\$214.75	\$238.89	\$221.28	\$211.88	\$240.07	\$221.38

Gross Amount Paid per Claim - Generic-Multi Source Drugs (Rebates not Subtracted)	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Avg Monthly
Generic-Multi Source Drugs: Average Paid / Claim (FFS & Encounter)	\$22.69	\$22.85	\$22.86	\$22.56	\$22.11	\$22.30	\$22.19	\$22.27	\$22.63	\$22.88	\$22.70	\$23.12	\$22.60
Mental Health Carve-Out Drugs	\$14.47	\$14.43	\$14.40	\$14.35	\$14.19	\$15.29	\$15.76	\$16.27	\$15.73	\$16.79	\$15.54	\$15.61	\$15.24
FFS Physical Health Drugs	\$21.65	\$23.80	\$24.72	\$21.60	\$21.63	\$20.80	\$22.43	\$22.70	\$23.23	\$22.45	\$23.82	\$24.08	\$22.74
Encounter Physical Health Drugs	\$24.83	\$24.98	\$24.99	\$24.71	\$24.16	\$24.14	\$23.84	\$23.82	\$24.41	\$24.46	\$24.50	\$25.06	\$24.49

Gross Amount Paid per Claim - Branded-Single Source Drugs (Rebates not Subtracted)	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Avg Monthly
Branded-Single Source Drugs: Average Paid / Claim (FFS & Encounter)	\$812.54	\$801.49	\$712.59	\$725.96	\$751.81	\$816.38	\$828.30	\$867.17	\$867.66	\$873.77	\$881.89	\$881.51	\$818.42
Mental Health Carve-Out Drugs	\$1,586.25	\$1,593.41	\$1,556.90	\$1,689.50	\$1,594.12	\$1,780.19	\$1,732.97	\$1,722.67	\$1,726.17	\$1,770.49	\$1,750.80	\$1,801.58	\$1,693.09
FFS Physical Health Drugs	\$497.82	\$468.02	\$429.55	\$437.81	\$401.30	\$479.65	\$476.83	\$506.23	\$473.10	\$496.52	\$506.98	\$505.65	\$473.29
Encounter Physical Health Drugs	\$775.82	\$764.57	\$677.22	\$680.77	\$713.61	\$764.07	\$780.17	\$820.64	\$820.55	\$823.13	\$830.81	\$824.14	\$772.96

Generic Drug Use Percentage	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Avg Monthly
Generic Drug Use Percentage	91.5%	91.3%	90.1%	90.2%	90.7%	91.3%	91.5%	91.7%	91.6%	91.6%	91.7%	91.6%	91.2%
Mental Health Carve-Out Drugs	97.3%	97.3%	97.3%	97.2%	97.3%	97.2%	97.2%	97.2%	97.1%	97.1%	97.0%	97.0%	97.2%
FFS Physical Health Drugs	86.0%	85.5%	83.7%	85.9%	86.4%	86.7%	87.1%	87.0%	87.3%	87.3%	86.9%	87.1%	86.4%
Encounter Physical Health Drugs	90.3%	90.1%	88.6%	88.7%	89.3%	90.0%	90.3%	90.5%	90.4%	90.4%	90.5%	90.4%	90.0%

Preferred Drug Use Percentage	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25	Jun-25	Avg Monthly
Preferred Drug Use Percentage	88.88%	88.58%	88.53%	88.48%	88.41%	88.34%	88.44%	88.42%	88.46%	88.49%	88.48%	88.51%	88.5%
Mental Health Carve-Out Drugs	86.71%	86.67%	86.51%	86.49%	86.52%	86.36%	86.28%	86.27%	86.27%	86.30%	86.29%	86.37%	86.4%
FFS Physical Health Drugs	94.55%	94.61%	94.34%	94.49%	94.67%	94.57%	94.41%	93.69%	94.21%	94.38%	93.96%	94.10%	94.3%
Encounter Physical Health Drugs	89.26%	88.89%	88.88%	88.81%	88.72%	88.67%	88.81%	88.80%	88.86%	88.87%	88.89%	88.92%	88.9%

Amount Paid on the Claim = 1) Ingredient Cost ((AAAC/NADAC/WAC) x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount



Top 40 Drugs by Gross Amount Paid (FFS Only) - Fourth Quarter 2025

Rank	Drug	PDL Class	Amount Paid	% Total FFS Costs	Claim Count	Avg Paid per Claim	PDL
1	VRAYLAR*	Antipsychotics, 2nd Gen	\$6,944,194	13.2%	4,951	\$1,403	Y
2	INVEGA SUSTENNA	Antipsychotics, Parenteral	\$6,102,848	11.6%	2,217	\$2,753	Y
3	REXULTI*	Antipsychotics, 2nd Gen	\$3,468,093	6.6%	2,480	\$1,398	V
4	ABILIFY MAINTENA	Antipsychotics, Parenteral	\$3,041,882	5.8%	1,223	\$2,487	Y
5	CAPLYTA*	Antipsychotics, 2nd Gen	\$2,158,511	4.1%	1,440	\$1,499	V
6	SPRAVATO*	Antidepressants	\$1,948,901	3.7%	1,448	\$1,346	V
7	INVEGA TRINZA	Antipsychotics, Parenteral	\$1,618,309	3.1%	196	\$8,257	Y
8	ARISTADA	Antipsychotics, Parenteral	\$1,262,935	2.4%	498	\$2,536	Y
9	AUVELITY	Antidepressants	\$1,174,521	2.2%	1,211	\$970	V
10	TRINTELLIX	Antidepressants	\$1,148,683	2.2%	2,438	\$471	V
11	LYBALVI*	Antipsychotics, 2nd Gen	\$851,752	1.6%	582	\$1,463	V
12	BUPROPION XL	Antidepressants	\$825,868	1.6%	60,454	\$14	Y
13	ABILIFY ASIMTUFII	Antipsychotics, Parenteral	\$800,080	1.5%	151	\$5,299	Y
14	SERTRALINE HCL	Antidepressants	\$726,895	1.4%	62,717	\$12	Y
15	QELBREE*	ADHD Drugs	\$681,433	1.3%	1,414	\$482	Y
16	TRAZODONE HCL	Antidepressants	\$670,516	1.3%	55,237	\$12	V
17	DULOXETINE HCL	Antidepressants	\$631,493	1.2%	39,446	\$16	Y
18	FLUOXETINE HCL	Antidepressants	\$624,613	1.2%	48,682	\$13	Y
19	ESCITALOPRAM OXALATE	Antidepressants	\$619,031	1.2%	48,755	\$13	Y
20	INVEGA HAFYERA	Antipsychotics, Parenteral	\$426,283	0.8%	25	\$17,051	Y
21	BUSPIRONE HCL	STC 07 - Ataractics, Tranquilizers	\$425,531	0.8%	32,481	\$13	
22	LAMOTRIGINE	Antiepileptics, Outpatient	\$419,503	0.8%	33,640	\$12	Y
23	DAYBUE*	STC 99 - Miscellaneous	\$358,487	0.7%	12	\$29,874	N
24	ARIPIPRAZOLE*	Antipsychotics, 2nd Gen	\$343,149	0.7%	23,825	\$14	Y
25	BIKTARVY	HIV	\$329,648	0.6%	96	\$3,434	Y
26	QUETIAPINE FUMARATE*	Antipsychotics, 2nd Gen	\$287,126	0.5%	22,088	\$13	Y
27	UZEDY	Antipsychotics, Parenteral	\$285,897	0.5%	98	\$2,917	Y
28	ATOMOXETINE HCL*	ADHD Drugs	\$257,481	0.5%	10,935	\$24	Y
29	VENLAFAXINE HCL ER	Antidepressants	\$248,515	0.5%	17,811	\$14	Y
30	Inj, Nusinersen, 0.1mg	Physican Administered Drug	\$246,012	0.5%	1	\$246,012	
31	SERTRALINE HCL	Antidepressants	\$240,661	0.5%	1,547	\$156	V
32	MAVYRET*	Hepatitis C, Direct-Acting Antivirals	\$226,127	0.4%	18	\$12,563	Y
33	COBENFY*	Antipsychotics, 2nd Gen	\$223,324	0.4%	146	\$1,530	V
34	MIRTAZAPINE	Antidepressants	\$221,795	0.4%	14,853	\$15	Y
35	OLANZAPINE*	Antipsychotics, 2nd Gen	\$206,958	0.4%	14,408	\$14	Y
36	GUANFACINE HCL ER	ADHD Drugs	\$206,450	0.4%	14,643	\$14	Y
37	OZEMPIC*	Diabetes, GLP-1 Receptor Agonists and GIP The	\$193,304	0.4%	309	\$626	N
38	SUBLOCADE	Substance Use Disorders, Opioid & Alcohol	\$191,737	0.4%	97	\$1,977	Y
39	LAMOTRIGINE ER	Antiepileptics, Outpatient	\$181,739	0.3%	5,147	\$35	V
40	Inj Pembrolizumab	Physican Administered Drug	\$181,237	0.3%	56	\$3,236	
Top 40 Aggregate:			\$41,001,524		527,776	\$8,750	
All FFS Drugs Totals:			\$52,681,300		772,975	\$666	

* Drug requires Prior Authorization

Notes

- FFS Drug Gross Costs only, rebates not subtracted
- PDL Key: Y=Preferred, N=Non-Preferred, V=Voluntary, Blank=Non PDL Class
- Amount Paid on the Claim = 1) Ingredient Cost ((AAAC/NADAC/WAC) x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount



Top 40 Physical Health Drugs by Gross Amount Paid (FFS Only) - Fourth Quarter 2025

Rank	Drug	PDL Class	Amount Paid	% Total FFS Costs	Claim Count	Avg Paid per Claim	PDL
1	BIKTARVY	HIV	\$329,648	3.9%	96	\$3,434	Y
2	Inj, Nusinersen, 0.1mg	Physican Administered Drug	\$246,012	2.9%	1	\$246,012	
3	MAVYRET*	Hepatitis C, Direct-Acting Antivirals	\$226,127	2.7%	18	\$12,563	Y
4	OZEMPIC*	Diabetes, GLP-1 Receptor Agonists and GIP The	\$193,304	2.3%	309	\$626	N
5	SUBLOCADE	Substance Use Disorders, Opioid & Alcohol	\$191,737	2.3%	97	\$1,977	Y
6	Inj Pembrolizumab	Physican Administered Drug	\$181,237	2.1%	56	\$3,236	
7	JARDIANCE	Diabetes, SGLT-2 Inhibitors	\$139,303	1.6%	380	\$367	Y
8	ELIQUIS	Anticoagulants, Oral and SQ	\$136,014	1.6%	347	\$392	Y
9	MOUNJARO*	Diabetes, GLP-1 Receptor Agonists and GIP The	\$117,327	1.4%	168	\$698	N
10	EVEROLIMUS*	Antineoplastics, Newer	\$116,343	1.4%	13	\$8,949	
11	EPIDIOLEX*	Antiepileptics, Outpatient	\$114,840	1.4%	55	\$2,088	N
12	Inj Fam-Trastu Deru-Nxki 1mg	Physican Administered Drug	\$114,446	1.4%	7	\$16,349	
13	TRIKAFTA*	Cystic Fibrosis	\$111,744	1.3%	14	\$7,982	N
14	SKYRIZI ON-BODY*	Targeted Immune Modulators	\$110,697	1.3%	11	\$10,063	N
15	TRULICITY*	Diabetes, GLP-1 Receptor Agonists and GIP The	\$102,808	1.2%	145	\$709	Y
16	BRIXADI	Substance Use Disorders, Opioid & Alcohol	\$101,213	1.2%	66	\$1,534	Y
17	IMCIVREE*	Weight Management Drugs	\$98,328	1.2%	3	\$32,776	
18	Injection, Ocrelizumab, 1 Mg	Physican Administered Drug	\$89,146	1.1%	10	\$8,915	
19	STELARA*	Targeted Immune Modulators	\$88,100	1.0%	4	\$22,025	N
20	Sacituzumab Govitecan-Hziy	Physican Administered Drug	\$78,358	0.9%	16	\$4,897	
21	EMVERM	STC 31 - Antiparasitics	\$74,672	0.9%	3	\$24,891	
22	WINREVAIR*	Pulmonary Arterial Hypertension Parenteral Dru	\$74,313	0.9%	5	\$14,863	N
23	KISQALI*	Antineoplastics, Newer	\$71,898	0.9%	6	\$11,983	
24	HUMIRA(CF) PEN*	Targeted Immune Modulators	\$70,757	0.8%	13	\$5,443	Y
25	FINTEPLA*	Antiepileptics, Outpatient	\$66,430	0.8%	5	\$13,286	N
26	BUPRENORPHINE-NALOXONE*	Substance Use Disorders, Opioid & Alcohol	\$61,043	0.7%	951	\$64	Y
27	SLYND	Contraceptives	\$58,643	0.7%	196	\$299	
28	DEXCOM G7 SENSOR*	Diabetic Supplies, CGM	\$58,212	0.7%	253	\$230	Y
29	Injection, Nivolumab	Physican Administered Drug	\$57,015	0.7%	27	\$2,112	
30	RINVOQ*	Targeted Immune Modulators	\$55,779	0.7%	19	\$2,936	N
31	COSENTYX SENSOREADY (2 PENS)*	Targeted Immune Modulators	\$54,727	0.6%	7	\$7,818	N
32	LISDEXAMFETAMINE DIMESYLATE*	ADHD Drugs	\$54,343	0.6%	855	\$64	Y
33	Inj., Cemiplimab-Rwlc, 1 Mg	Physican Administered Drug	\$49,989	0.6%	9	\$5,554	
34	IBRANCE*	Antineoplastics, Newer	\$49,416	0.6%	3	\$16,472	
35	ALBUTEROL SULFATE HFA	Beta-Agonists, Inhaled Short-Acting	\$49,160	0.6%	1,856	\$26	Y
36	Inj, Faricimab-Svoa, 0.1mg	Physican Administered Drug	\$48,842	0.6%	85	\$575	
37	CREON	Pancreatic Enzymes	\$48,412	0.6%	43	\$1,126	Y
38	ENBREL SURECLICK*	Targeted Immune Modulators	\$48,300	0.6%	13	\$3,715	Y
39	SYMBICORT	Corticosteroids/Beta-Agonist Combination, Inh:	\$46,687	0.6%	218	\$214	Y
40	Altuviiiio Per Factor Viii lu	Physican Administered Drug	\$46,642	0.6%	2	\$23,321	
Top 40 Aggregate:			\$4,032,011		6,385	\$13,015	
All FFS Drugs Totals:			\$8,455,265		87,723	\$649	

* Drug requires Prior Authorization

Notes

- FFS Drug Gross Costs only, rebates not subtracted
- PDL Key: Y=Preferred, N=Non-Preferred, V=Voluntary, Blank=Non PDL Class
- Amount Paid on the Claim = 1) Ingredient Cost ((AAAC/NADAC/WAC) x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount